Reviva Pharmaceuticals (RVPH) News Today $0.92 +0.07 (+8.82%) (As of 10:30 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 Time Period August 21 at 1:00 PM | msn.comExplainer-Big Tech wants AI to be regulated. Why do they oppose a California AI bill?August 21 at 6:00 AM | globenewswire.comReviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq RulesAugust 18, 2024 | americanbankingnews.comMaxim Group Reiterates "Hold" Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)August 17, 2024 | msn.comMaxim Group Downgrades Reviva Pharmaceuticals Holdings (RVPH)August 14, 2024 | investorplace.comRVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024August 6, 2024 | finance.yahoo.comReviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary FibrosisJuly 9, 2024 | globenewswire.comReviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary HypertensionMay 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 29, 2024 | finance.yahoo.comReviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 29, 2024 | globenewswire.comReviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 28, 2024 | finance.yahoo.comReviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 28, 2024 | globenewswire.comReviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 22, 2024 | finance.yahoo.comRVPH: Enrollment Right Around the CornerMay 21, 2024 | globenewswire.comReviva to Participate in the BIO International ConventionMay 20, 2024 | edition.cnn.comReviva Pharmaceuticals Holdings, Inc.May 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 15, 2024 | finance.yahoo.comReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaMay 15, 2024 | globenewswire.comReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaMay 14, 2024 | investorplace.comRVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | globenewswire.comReviva Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 13, 2024 | globenewswire.comReviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International ConferenceMay 10, 2024 | prnewswire.comRVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPHMay 9, 2024 | globenewswire.comReviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual MeetingMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 4, 2024 | morningstar.comReviva Pharmaceuticals Holdings Inc Ordinary Shares RVPHApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHApril 28, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHApril 25, 2024 | finance.yahoo.comRVPH: Full Year 2023 ResultsApril 25, 2024 | businesswire.comRVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPHApril 24, 2024 | marketbeat.comBrokers Set Expectations for Reviva Pharmaceuticals Holdings, Inc.'s Q1 2024 Earnings (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Equities research analysts at HC Wainwright cut their Q1 2024 EPS estimates for shares of Reviva Pharmaceuticals in a research report issued to clients and investors on Monday, April 22nd. HC Wainwright analyst R. Selvaraju now eApril 23, 2024 | marketbeat.comHC Wainwright Weighs in on Reviva Pharmaceuticals Holdings, Inc.'s Q1 2025 Earnings (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a research note issued on Monday, April 22nd. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.33) per sApril 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)April 22, 2024 | marketbeat.comReviva Pharmaceuticals (NASDAQ:RVPH) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Reviva Pharmaceuticals in a report on Monday.April 16, 2024 | marketbeat.comReviva Pharmaceuticals' (RVPH) "Speculative Buy" Rating Reiterated at BenchmarkBenchmark reissued a "speculative buy" rating and issued a $17.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday.April 15, 2024 | msn.comRVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER DataApril 15, 2024 | investorplace.comRVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023April 15, 2024 | finanznachrichten.deReviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in SchizophreniaApril 15, 2024 | finanznachrichten.deReviva Pharmaceuticals: Reviva Reports Full Year 2023 Financial Results and Recent Business HighlightsApril 15, 2024 | globenewswire.comReviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in SchizophreniaApril 15, 2024 | globenewswire.comReviva Reports Full Year 2023 Financial Results and Recent Business HighlightsApril 14, 2024 | marketbeat.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest UpdateReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 1,060,000 shares, a growth of 62.9% from the March 15th total of 650,700 shares. Based on an average daily volume of 331,800 shares, the days-to-cover ratio is currently 3.2 days.March 28, 2024 | finance.yahoo.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual MeetingMarch 28, 2024 | globenewswire.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual MeetingMarch 27, 2024 | finance.yahoo.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual MeetingMarch 25, 2024 | markets.businessinsider.comOptimistic Buy Rating for Reviva Pharmaceuticals Based on Brilaroxazine’s Broad Therapeutic PromiseMarch 25, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Reviva Pharmaceuticals in a report on Monday.March 15, 2024 | marketbeat.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Down 15.9% in FebruaryReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of a large decline in short interest in February. As of February 29th, there was short interest totalling 858,100 shares, a decline of 15.9% from the February 14th total of 1,020,000 shares. Based on an average daily volume of 432,200 shares, the days-to-cover ratio is currently 2.0 days.March 14, 2024 | finance.yahoo.comRVPH Mar 2024 3.000 putMarch 11, 2024 | globenewswire.comReviva to Present at the UBS Virtual CNS Day Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address What Is the $7,882 Stimulus Payment 2024? (Ad)Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter. Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here. RVPH Media Mentions By Week RVPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVPH News Sentiment▼0.520.44▲Average Medical News Sentiment RVPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVPH Articles This Week▼52▲RVPH Articles Average Week Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RLMD News PLX News PMVP News ELUT News COYA News MIST News CLRB News BYSI News GNLX News SLS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVPH) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
